Format

Send to

Choose Destination
Adv Exp Med Biol. 2018;1098:131-150. doi: 10.1007/978-3-319-97421-7_7.

Cardiac Extracellular Matrix Modification as a Therapeutic Approach.

Hall ML1,2, Ogle BM3,4,5,6,7.

Author information

1
Department of Biomedical Engineering, University of Minnesota - Twin Cities, Minneapolis, MN, USA.
2
Stem Cell Institute, University of Minnesota - Twin Cities, Minneapolis, MN, USA.
3
Department of Biomedical Engineering, University of Minnesota - Twin Cities, Minneapolis, MN, USA. ogle@umn.edu.
4
Stem Cell Institute, University of Minnesota - Twin Cities, Minneapolis, MN, USA. ogle@umn.edu.
5
Masonic Cancer Center, University of Minnesota - Twin Cities, Minneapolis, MN, USA. ogle@umn.edu.
6
Lillehei Heart Institute, University of Minnesota - Twin Cities, Minneapolis, MN, USA. ogle@umn.edu.
7
Institute for Engineering in Medicine, University of Minnesota - Twin Cities, Minneapolis, MN, USA. ogle@umn.edu.

Abstract

The cardiac extracellular matrix (cECM) is comprised of proteins and polysaccharides secreted by cardiac cell types, which provide structural and biochemical support to cardiovascular tissue. The roles of cECM proteins and the associated family of cell surface receptor, integrins, have been explored in vivo via the generation of knockout experimental animal models. However, the complexity of tissues makes it difficult to isolate the effects of individual cECM proteins on a particular cell process or disease state. The desire to further dissect the role of cECM has led to the development of a variety of in vitro model systems, which are now being used not only for basic studies but also for testing drug efficacy and toxicity and for generating therapeutic scaffolds. These systems began with 2D coatings of cECM derived from tissue and have developed to include recombinant ECM proteins, ECM fragments, and ECM mimics. Most recently 3D model systems have emerged, made possible by several developing technologies including, and most notably, 3D bioprinting. This chapter will attempt to track the evolution of our understanding of the relationship between cECM and cell behavior from in vivo model to in vitro control systems. We end the chapter with a summary of how basic studies such as these have informed the use of cECM as a direct therapy.

KEYWORDS:

Bioink; Bioprinting; Cardiac repair; Cardiac therapy; ECM mimetic; Recombinant ECM

PMID:
30238369
DOI:
10.1007/978-3-319-97421-7_7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center